Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 7,950.00
-300.00 (-3.64%)
Aug 12, 2026, 3:30 PM KST
Hyundai Bioscience Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 796,152 | 476,832 | 561,851 | 1,038,982 | 1,087,244 | 976,101 | |
Market Cap Growth | 42.93% | -15.13% | -45.92% | -4.44% | 11.39% | -6.92% |
Enterprise Value | 773,445 | 447,473 | 579,143 | 1,031,571 | 1,069,527 | 969,321 |
Last Close Price | 8250.00 | 4965.00 | 7055.00 | 12295.97 | 12908.41 | 11895.53 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 254.10 | 135.57 | 37.33 | 109.58 | 138.48 | 105.62 |
PB Ratio | 7.11 | 4.31 | 14.25 | 22.95 | 18.67 | 15.85 |
P/TBV Ratio | 13.31 | 8.14 | 89.63 | 73.68 | 43.38 | 34.98 |
P/FCF Ratio | - | - | 269.15 | - | - | - |
P/OCF Ratio | - | - | 248.93 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 246.85 | 127.22 | 38.48 | 108.80 | 136.22 | 104.89 |
EV/EBITDA Ratio | - | - | 394.62 | - | - | - |
EV/EBIT Ratio | - | - | 694.59 | - | - | - |
EV/FCF Ratio | - | - | 277.44 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.14 | 0.16 | 0.67 | 0.12 | 0.11 | 0.25 |
Debt / EBITDA Ratio | - | - | 18.12 | - | - | - |
Debt / FCF Ratio | - | - | 12.74 | - | - | - |
Net Debt / Equity Ratio | -0.20 | -0.20 | 0.58 | -0.14 | -0.21 | -0.11 |
Net Debt / EBITDA Ratio | 1.32 | 1.32 | 15.63 | 0.75 | 0.51 | 1.02 |
Net Debt / FCF Ratio | 1.42 | 1.22 | 10.99 | 0.96 | 0.69 | 1.57 |
Asset Turnover | 0.02 | 0.04 | 0.25 | 0.16 | 0.11 | 0.11 |
Inventory Turnover | 2.36 | 3.18 | 1.78 | 1.62 | 1.63 | 1.59 |
Quick Ratio | 2.30 | 2.18 | 0.14 | 1.77 | 2.23 | 1.73 |
Current Ratio | 2.40 | 2.25 | 0.25 | 2.18 | 2.67 | 2.02 |
Return on Equity (ROE) | -18.55% | -29.45% | -16.26% | -28.02% | -26.39% | -35.21% |
Return on Assets (ROA) | -8.54% | -11.44% | 0.86% | -10.20% | -22.24% | -6.66% |
Return on Invested Capital (ROIC) | -20.87% | -24.09% | 1.65% | -23.13% | -52.30% | -14.85% |
Return on Capital Employed (ROCE) | -16.50% | -16.30% | 2.10% | -21.40% | -45.10% | -14.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.68% | -4.64% | -1.23% | -1.40% | -1.45% | -2.05% |
FCF Yield | -2.01% | -3.83% | 0.37% | -0.63% | -1.66% | -0.44% |
Buyback Yield / Dilution | -17.73% | -18.06% | -0.10% | -1.04% | -6.64% | -2.79% |